Genmab is going through a growth spurt and expands on three continents

Genmab keeps expanding its workforce in Europe, the US and Japan to prepare for handling drug commercialization on its own.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

If Genmab's drug tisotumab vedotin is approved in the US in October as expected, the firm will take on its own sales and marketing for the first time.

The Danish biotech company is currently expanding its workforce to prepare for participating in commercial activities with US company Seagen, formerly Seattle Genetics, with which it shares the rights for tisotumab vedotin equally.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs